BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows

BIOLARGO, INC.

Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.
Net loss narrowed to $1.1M in Q3 (from $1.5M) and $2.6M YTD (from $3.6M).
Current assets $7.4M, cash $3.9M; stockholders' equity $6.0M as of Sept 30, 2024.
CEO says tenth consecutive year of record revenue; expects 2025 to be another record.
Investing in production for national rollout of Clyra Medical Technologies products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.